| International uniform response criteria for multiple myeloma BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ... Leukemia 20 (9), 1467-1473, 2006 | 3458 | 2006 |
| Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review):[RETIRED] Report of the Quality Standards … JM Miyasaki, K Shannon, V Voon, B Ravina, G Kleiner-Fisman, ... Neurology 66 (7), 996-1002, 2006 | 686 | 2006 |
| The clinically important difference on the unified Parkinson's disease rating scale LM Shulman, AL Gruber-Baldini, KE Anderson, PS Fishman, SG Reich, ... Archives of neurology 67 (1), 64-70, 2010 | 555 | 2010 |
| Brain networks associated with cognitive reserve in healthy young and old adults Y Stern, C Habeck, J Moeller, N Scarmeas, KE Anderson, HJ Hilton, ... Cerebral cortex 15 (4), 394-402, 2005 | 552 | 2005 |
| Presentation of viral antigen controlled by a gene in the major histocompatibility complex V Cerundolo, J Alexander, K Anderson, C Lamb, P Cresswell, ... Nature 345 (6274), 449-452, 1990 | 503 | 1990 |
| Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease LM Shulman, LI Katzel, FM Ivey, JD Sorkin, K Favors, KE Anderson, ... JAMA neurology 70 (2), 183-190, 2013 | 450 | 2013 |
| CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 429 | 2012 |
| Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis N Scarmeas, E Zarahn, KE Anderson, CG Habeck, J Hilton, J Flynn, ... Archives of neurology 60 (3), 359-365, 2003 | 379 | 2003 |
| The evolution of disability in Parkinson disease LM Shulman, AL Gruber‐Baldini, KE Anderson, CG Vaughan, SG Reich, ... Movement disorders 23 (6), 790-796, 2008 | 350 | 2008 |
| Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease GM Pontone, JR Williams, KE Anderson, G Chase, SA Goldstein, S Grill, ... Movement disorders: official journal of the Movement Disorder Society 24 (9 …, 2009 | 335 | 2009 |
| Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease S Palmqvist, H Zetterberg, N Mattsson, P Johansson, ... Neurology 85 (14), 1240-1249, 2015 | 334 | 2015 |
| Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY) E van Duijn, D Craufurd, AAM Hubers, EJ Giltay, R Bonelli, H Rickards, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (12), 1411-1418, 2014 | 310 | 2014 |
| Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease DA Wolk, BC Dickerson, Alzheimer’s Disease Neuroimaging Initiative, ... Proceedings of the National Academy of Sciences 107 (22), 10256-10261, 2010 | 273 | 2010 |
| Subregional neuroanatomical change as a biomarker for Alzheimer's disease D Holland, JB Brewer, DJ Hagler, C Fennema-Notestine, AM Dale, ... Proceedings of the National Academy of Sciences 106 (49), 20954-20959, 2009 | 246 | 2009 |
| Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects N Scarmeas, E Zarahn, KE Anderson, J Hilton, J Flynn, RL Van Heertum, ... Neuroimage 19 (3), 1215-1227, 2003 | 207 | 2003 |
| Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study HH Fernandez, SA Factor, RA Hauser, J Jimenez-Shahed, WG Ondo, ... Neurology 88 (21), 2003-2010, 2017 | 197 | 2017 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 195 | 2021 |
| Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial S Frank, CM Testa, D Stamler, E Kayson, C Davis, MC Edmondson, ... Jama 316 (1), 40-50, 2016 | 187 | 2016 |
| Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial KE Anderson, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojärvi, ... The Lancet Psychiatry 4 (8), 595-604, 2017 | 184 | 2017 |
| Vascular burden and Alzheimer disease pathologic progression RY Lo, WJ Jagust, M Weiner, P Aisen, M Weiner, P Aisen, R Petersen, ... Neurology 79 (13), 1349-1355, 2012 | 183 | 2012 |
Ann Gruber-BaldiniUniversity of Maryland School of Medicine在 som.umaryland.edu 的电子邮件经过验证
